Third Wave currently markets IVD tests for DNA detection of the Human Papillomavirus (CervistaTM HPV). In addition to these IVD products, Third Wave has a broad menu of Analyte Specific Reagents currently used by over 210 clinical laboratories in the United States. Third Wave's future includes FDA submissions for High-Risk HPV Screening and 16/18 Genotyping tests as well as continued expansion of our test menu through development of new ASRs.
*Analyte Specific Reagent. Analytical and performance characteristics are not established.